Clinical Trials Browser

Phase 3 × Active not recruiting × trastuzumab deruxtecan × Clear all

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT04739761 2026-02-11

DESTINY-B12

Phase 3 Active not recruiting

506 enrolled 27 charts

Brain Neoplasms, Breast Neoplasms

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05048797 2025-12-23

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase 3 Active not recruiting

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04622319 2025-05-09

DESTINY-Breast05

Phase 3 Active not recruiting

HER2-Positive Primary Breast Cancer